

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, or claims in the application:

Listing of Claims

1. (Currently Amended): A method for treatment of a patient suffering from major depressive disorder, the method comprising administering to said patient at a time selected from the group consisting of, as an initial treatment, as soon as possible and upon presentation of said patient to a physician or other health care provider an effective amount of an antidepressant in combination with an antipsychotic drug, said major depressive disorder categorized as non-treatment resistant and non-psychotic.
2. (Currently Amended): A method for treatment of a patient suffering from unipolar depression, the method comprising administering to said patient at a time selected from the group consisting of, as an initial treatment, as soon as possible and upon presentation of said patient to a physician or other health care provider an effective amount of an antidepressant in combination with an antipsychotic drug, said unipolar depression categorized as non-treatment resistant and non-psychotic.
3. (Currently Amended): A method for treatment of a non-psychotic patient selected from the group consisting of (a) a patient having cognitive distortions with functional impairment or health hazards, wherein the method comprising administering to said patient as an initial treatment or as soon as possible, or upon presentation to a physician or a health care provider, or ~~or~~ and (b) of a patient undergoing smoking cessation or nicotine withdrawal, the method comprising wherein in either case (a) or (b) the method includes administering to said non-psychotic patient an effective amount of an antidepressant in combination with an antipsychotic drug, and wherein said antipsychotic drug is administered at a low dose.
4. (Original): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is an atypical antipsychotic.

5. (Original): The method of Claim 4 wherein said atypical antipsychotic drug is selected from the group consisting of quetiapine, risperidone, ziprasidone, and pharmaceutically acceptable salts thereof.

6. (Currently amended): The method of Claim 4 wherein said atypical antipsychotic drug is selected from the group consisting of olanzapine, iloperidone, ~~Org-5222~~, melperone, amperozide, ~~SM-9018, JL-13~~, and pharmaceutically acceptable salts thereof.

7. (Original): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is a dopamine system stabilizer.

8. (Original): The method of Claim 7, wherein said dopamine system stabilizer is aripiprazole, or pharmaceutically acceptable salts thereof.

9. (Original): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is an antipsychotic administered at a low dose.

10. (Original): The method of Claim 9, wherein said antipsychotic drug is selected from the group consisting of perphenazine, trifluoperazine, zotepine, flupenthixol, amisulpride, and sulpiride.

11. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is selected from the group consisting of serotonin reuptake inhibitors, a selective norepinephrine reuptake inhibitors, combined action SSRI/SNRI, serotonin-2 antagonist/reuptake inhibitors, an antidepressant with alpha-2 antagonism plus serotonin-2 and serotonin-3 antagonism, an antidepressant with serotonin/norepinephrine/dopamine reuptake inhibition and an antidepressant with norepinephrine and dopamine reuptake inhibition.

12. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is selected from the group consisting of 5-HT-1alpha antagonist, 5-HT-1beta antagonist, 5-HT1A

receptor agonists, 5-HT_{1A} receptor agonists and antagonists, 5-HT₂ receptor antagonists, viloxazine hydrochloride, dehydroepiandrosterone, NMDA receptor antagonists, AMPA receptor potentiators, substance P antagonists/ neurokinin-1 receptor antagonists, nonpeptide Substance P antagonist, neurokinin 2 antagonists, neurokinin 3 antagonists, corticotropin-releasing factor receptor antagonists, antiglucocorticoid medications, glucocorticoid receptor antagonists, cortisol blocking agents, nitric oxide synthase inhibitors, inhibitors of phosphodiesterase, enkephalinase inhibitors, GABA-A receptor agonists, free radical trapping agents, atypical MAOI's, selective MAOI inhibitors, hormones, folinic acid, leucovorin, tramadol, and tryptophan.

13. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is a selective serotonin reuptake inhibitor.

14. (Previously presented): The method of Claim 11, wherein the antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof.

15. (Previously presented): The method of Claim 11, wherein the antidepressant is clomipramine.

16. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is risperidone.

17. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is quetiapine.

18. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is olanzapine.

19. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is aripiprazole.
20. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is risperidone.
21. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is quetiapine.
22. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is olanzapine.
23. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is aripiprazole.
24. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is risperidone.
25. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is quetiapine.
26. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is olanzapine.
27. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is aripiprazole.
28. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is risperidone.

29. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is quetiapine.

30. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is olanzapine.

31. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is aripiprazole.

32. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is ziprasidone.

33. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is ziprasidone.

34. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is ziprasidone.

35. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is ziprasidone.

36. (Original): The method of Claims 1, 2, or 3, wherein the antipsychotic is selected from the group consisting of risperidone, quetiapine, olanzapine, ziprasidone and aripiprazole, and the effective amount is from 0.5mg to 4mg for risperidone, from 25mg to 400mg for quetiapine, from 2.5mg to 10mg for olanzapine, from 10mg to 40 mg for ziprasidone, and 2.5mg to 15 mg for aripiprazole.

37. (Original): The method of Claims 1, 2, or 3, wherein an effective amount of the antidepressant is its recommended therapeutic dose, or its effective starting dose.

38. (Original): The method of Claims 1, 2, or 3, wherein the administration is oral.

39. (Cancelled)

40. (Cancelled)

41. (Currently amended): The method of Claims 1 or 2, wherein treatment is given for ~~preventing~~ resisting suicide.

42. (Currently amended): The method of Claims ~~1 or~~ 2, wherein treatment is ~~given~~ effected for at least one of the group consisting of ~~preventing disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against~~ inhibiting the development of tolerance toward the antidepressant, ~~or~~ remedying the development of tolerance toward the antidepressant, ~~to provide~~ providing a neuroprotective effect, ~~to avoid~~ avoiding a paradoxical effect of antidepressant ~~to sensitize~~ sensitizing patients to depression, ~~to avoid~~ avoiding worsening of depression from the antidepressant, ~~or treat~~ treating worsening of depression from the antidepressant, ~~to treat~~ and treating residual symptoms of depression, ~~or for preventing the development of delusional/psychotic depression.~~

43. (Currently amended): The method of Claims 1, ~~or~~ 2 or 3, wherein said treatment is given as ~~initial treatment or as soon as possible, or upon presentation to a physician or a health care provider~~ for preventing suicide.

44. (Cancelled)

45. (Cancelled)

46. (Cancelled)

47. (Cancelled)

48. (Currently amended): The method of ~~Claims 16 to 35~~ Claim 1, wherein treatment is ~~given~~ effected for at least one of the group consisting of ~~preventing disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against~~ inhibiting the development of tolerance toward the antidepressant, ~~or~~ remedying the development of tolerance toward the antidepressant, ~~to provide~~ providing a neuroprotective effect, ~~to avoid~~ avoiding a paradoxical effect of the antidepressant ~~to sensitize~~ sensitizing patients to depression, ~~to avoid~~ avoiding worsening of depression from the antidepressant, ~~or treat~~ treating worsening of depression from the antidepressant, ~~to treat~~ and treating residual symptoms of depression, ~~or for preventing the development of delusional/psychotic depression.~~

49. (Currently Amended): The method of Claim 3, wherein treatment is given for cognitive ~~distortion(s)~~ distortions, when the cognitive ~~distortion(s)~~ distortions lead to functional impairment, or a serious health hazard.

50. (Original): The method of Claim 3, wherein treatment is given for smoking cessation or nicotine withdrawal.

51. (Previously presented): The method of Claim 13, wherein the antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof.

52. (Previously presented): The method of Claim 13, wherein the antidepressant is clomipramine.

53. (Currently Amended): The method of Claim 2, wherein treatment is ~~given~~ effected for at least one of the group consisting of ~~preventing~~ inhibiting disease progression, modifying the course of depression, ~~delaying/preventing relapse, preventing the recurrence of depression, protecting against~~ inhibiting the development of tolerance

toward the antidepressant, ~~or~~ remedying the development of tolerance toward the antidepressant, ~~to provide~~ providing a neuroprotective effect, ~~to avoid~~ avoiding a paradoxical effect of antidepressant ~~to sensitize~~ sensitizing patients to depression, ~~to avoid~~ inhibiting worsening of depression from the antidepressant, ~~or treat~~ treating worsening of depression from the antidepressant, ~~to treat~~ and treating residual symptoms of depression, ~~or for preventing the development of delusional/psychotic depression.~~

54. (Currently Amended): The method of Claim 3, wherein treatment is ~~given~~ effected for at least one of the group consisting of ~~preventing~~ inhibiting disease progression, modifying the course of depression, ~~delaying/preventing relapse, preventing the recurrence of depression, protecting against~~ inhibiting the development of tolerance toward the antidepressant, ~~or~~ remedying the development of tolerance toward the antidepressant, ~~to provide~~ providing a neuroprotective effect, ~~to avoid~~ avoiding a paradoxical effect of antidepressant ~~to sensitize~~ sensitizing patients to depression, ~~to avoid~~ avoiding worsening of depression from the antidepressant, ~~or treat~~ treating worsening of depression from the antidepressant, ~~treat~~ and treating residual symptoms of depression, ~~or for preventing the development of delusional/psychotic depression.~~

55. (New): The method of Claim 1 including treating substantially all patients treated by said physician or other health care provider by said method, wherein said antipsychotic drug is administered at a low dose, and said treatment is given for resisting suicide.

56. (New): The method of Claim 1 including treating a plurality of said patients by said method, wherein said antipsychotic drug is administered at a low dose, and said treatment is given for resisting suicide.

57. (New): The method of Claim 2 including treating substantially all patients treated by said physician or other health care provider by said method, wherein said antipsychotic drug is administered at a low dose, and said treatment is given for resisting suicide.

58. (New): The method of Claim 2 including treating a plurality of said patients by said method, wherein said antipsychotic drug is administered at a low dose, and said treatment is given for resisting suicide.

59. (New): The method of Claims 1, 2, wherein treatment is given for resisting suicide, and wherein treatment is given for the benefit of the group of patients being treated by said physician or health care provider.

60. (New): The method of Claims 55, 56, 57, or 58 wherein treatment is given for the benefit of the group of patients being treated by said physician or health care provider.

61. (New): The method of Claim 3, wherein treatment is given for resisting suicide.

62. (New): The method of Claim 3, wherein treatment is given for resisting suicide, and wherein treatment is given for the benefit of the group.

63. (New): The method of Claims 55, 57 or 61, wherein said antipsychotic drug is an atypical antipsychotic.

64. (New): The method of Claims 55, 57 or 61, wherein said atypical antipsychotic drug is selected from the group consisting of quetiapine, risperidone, ziprasidone, and pharmaceutically acceptable salts thereof.

65. (New): The method of Claims 1, 2, 55, 57 or 61, wherein the antipsychotic is the active metabolite of risperidone.

66. (New): The method of Claims 55, 57 or 61, wherein said atypical antipsychotic drug is selected from the group consisting of olanzapine, iloperidone, melperone, amperozide, and pharmaceutically acceptable salts thereof.

67. (New): The method of Claims 55, 57 or 61, wherein said antipsychotic drug is a dopamine system stabilizer.

68. (New): The method of 55, 57 or 61, wherein said dopamine system stabilizer is aripiprazole, or pharmaceutically acceptable salts thereof.

69. (New): The method of 55, 57 or 61, wherein said antipsychotic drug is selected from the group consisting of perphenazine, trifluoperazine, zotepine, flupenthixol, amisulpride, and sulpiride.

70. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is selected from the group consisting of serotonin reuptake inhibitors, a selective norepinephrine reuptake inhibitors, combined action SSRI/SNRI, serotonin-2 antagonist/reuptake inhibitors, an antidepressant with alpha-2 antagonism plus serotonin-2 and serotonin-3 antagonism, an antidepressant with serotonin/norepinephrine/dopamine reuptake inhibition and an antidepressant with norepinephrine and dopamine reuptake inhibition.

71. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is selected from the group consisting of 5-HT-1alpha antagonist, 5-HT-1beta antagonist, 5-HT1A receptor agonists, 5-HT1A receptor agonists and antagonists, 5-HT2 receptor antagonists, viloxazine hydrochloride, dehydroepiandrosterone, NMDA receptor antagonists, AMPA receptor potentiators, substance P antagonists/ neurokinin-1 receptor antagonists, nonpeptide Substance P antagonist, neurokinin 2 antagonists, neurokinin 3 antagonists, corticotropin-releasing factor receptor antagonists, antiglucocorticoid medications, glucocorticoid receptor antagonists, cortisol blocking agents, nitric oxide synthetase inhibitors, inhibitors of phosphodiesterase, enkephalinase inhibitors, GABA-A receptor agonists, free radical trapping agents, atypical MAOI's, selective MAOI inhibitors, hormones, folinic acid, leucovorin, tramadol, and tryptophan.

72. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is a selective serotonin reuptake inhibitor.

73. (New): The method of 55, 57 or 61, wherein the antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof.

74. (New): The method of 55, 57 or 61, wherein the antidepressant is clomipramine.

75. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is risperidone.

76. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is quetiapine.

77. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is olanzapine.

78. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is aripiprazole.

79. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is risperidone.

80. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is quetiapine.

81. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is olanzapine.

82. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is aripiprazole.

83. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is risperidone.

84. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is quetiapine.

85. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is olanzapine.

86. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is aripiprazole.

87. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is risperidone.

88. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is quetiapine.

89. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is olanzapine.

90. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is aripiprazole.

91. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is ziprasidone.

92. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is ziprasidone.

93. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is ziprasidone.

94. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is ziprasidone.

95. (New): The method of Claims 55, 57 or 61, wherein the antipsychotic is selected from the group consisting of risperidone, quetiapine, olanzapine, ziprasidone and aripiprazole, and the effective amount is from 0.5mg to 4mg for risperidone, from 25mg to 400mg for quetiapine, from 2.5mg to 10mg for olanzapine, from 10mg to 40 mg for ziprasidone, and 2.5mg to 15 mg for aripiprazole.

96. (New): The method of Claims 55, 57 or 61, wherein an effective amount of the antidepressant is its recommended therapeutic dose, or its effective starting dose.

97. (New): The method of Claims 55, 57 or 61, wherein the administration is oral.

98. (New): The method of Claims 55, 57 or 61, wherein treatment is effected for at least one of the group consisting of delaying relapse; preventing relapse; and preventing the recurrence of depression.

99. (New): The method of Claims 55, 57 or 61, wherein treatment is effected for at least one of the group consisting of protecting against the development of tolerance toward the antidepressant; and remedying the development of tolerance toward the antidepressant.

100. (New): The method of Claims 1, 2, 55, 57 or 61, wherein treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of antidepressant to sensitize patients to depression; treating a paradoxical effect of antidepressant to sensitize

patients to depression; for avoiding worsening of depression from the antidepressant; and treating worsening of depression from the antidepressant.

101. (New): The method of Claims 1, 2, 55, 57 or 61, wherein treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of antidepressant sensitizing patients to depression and causing suicide; avoiding a paradoxical effect of antidepressant sensitizing patients to depression and causing suicidal ideation; treating a paradoxical effect of antidepressant sensitizing patients to depression and causing suicide; treating a paradoxical effect of antidepressant sensitizing patients to depression and causing suicidal ideation; avoiding worsening of depression from the antidepressant and causing suicide; avoiding worsening of depression from the antidepressant and causing suicidal ideation; treating worsening of depression from the antidepressant and causing suicide; and treating worsening of depression from the antidepressant and causing suicidal ideation.

102. (New): The method of Claims 55, 57 or 61, wherein treatment is given for providing a neuroprotective effect.

103. (New): The method of Claims 55, 57 or 61, wherein treatment is given for treating residual symptoms of depression.

104. (New): The method of Claims 55, 57 or 61, wherein the antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof.

105. (New): The method of Claims 55, 57 or 61, wherein the antidepressant is clomipramine.

106. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is ketamine.

107. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is ketamine, and wherein the antipsychotic are selected from the group consisting of perphenazine, trifluoperazine, zotepine, flupenthixol, amisulpride, and sulpiride.

108. (New): The method of Claims 55, 57 or 61, wherein said antidepressant is ketamine, and wherein the antipsychotic are selected from the group consisting of risperidone, quetiapine, olanzapine, ziprazidone, and aripiprazole, and the effective amount is from 0.5mg to 4 mg for risperidone, from 25mg to 400 mg for quetiapine, from 2.5mg to 10 mg for olanzapine, from 10-40mg for ziprazidone, and 2.5mg to 15mg for aripiprazole.

109. (New): A method for treatment of a patient suffering from major depressive disorder, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is effected for at least one of the group consisting of delaying relapse; preventing relapse; and preventing the recurrence of depression.

110. (New): A method for treatment of a patient suffering from unipolar depression, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is effected for at least one of the group consisting of delaying relapse; preventing relapse; and preventing the recurrence of depression.

111. (New): A method for treatment of a patient suffering from major depressive disorder, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is

effected for at least one of the group consisting of protecting against development of tolerance toward the antidepressant; and remedying the development of tolerance toward the antidepressant.

112. (New): A method for treatment of a patient suffering from unipolar depression, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is effected for at least one of the group consisting of protecting against development of tolerance toward the antidepressant; and remedying the development of tolerance toward the antidepressant.

113. (New): A method for treatment of a patient suffering from major depressive disorder, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of antidepressant to sensitize patients to depression; treating a paradoxical effect of antidepressant to sensitize patients to depression; for avoiding worsening of depression from the antidepressant; and treating worsening of depression from the antidepressant.

114. (New): A method for treatment of a patient suffering from unipolar depression, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of antidepressant to sensitize patients to depression; treating a paradoxical effect of antidepressant to sensitize patients to depression; for avoiding worsening of depression from the antidepressant; and treating worsening of depression from the antidepressant.

115. (New): a method for treatment of a patient suffering from major depressive disorder, the method comprising administering to said patient an effective amount of an

antidepressant in combination with an antipsychotic drug, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of antidepressant to sensitize patients to depression and causing suicide; avoiding a paradoxical effect of antidepressant to sensitize patients to depression and causing suicidal ideation; treating a paradoxical effect of antidepressant to sensitize patients to depression and causing suicide; treating a paradoxical effect of antidepressant to sensitize patients to depression and causing suicidal ideation; avoiding worsening of depression from the antidepressant and causing suicide; avoiding worsening of depression from the antidepressant and causing suicidal ideation; treating worsening of depression from the antidepressant and causing suicide; and treating worsening of depression from the antidepressant and causing suicidal ideation.

116. (New): A method for treatment of a patient suffering from unipolar depression, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of antidepressant to sensitize patients to depression and causing suicide; avoiding a paradoxical effect of antidepressant to sensitize patients to depression and causing suicidal ideation; treating a paradoxical effect of antidepressant to sensitize patients to depression and causing suicide; treating a paradoxical effect of antidepressant to sensitize patients to depression and causing suicidal ideation; avoiding worsening of depression from the antidepressant and causing suicide; avoiding worsening of depression from the antidepressant and causing suicidal ideation; treating worsening of depression from the antidepressant and causing suicide; and treating worsening of depression from the antidepressant and causing suicidal ideation.

117. (New): A method for treatment of a patient suffering from major depressive disorder, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said major depressive disorder

categorized as non-treatment resistant and non-psychotic, and wherein said treatment is given for treating residual symptoms of depression.

118. (New): A method for treatment of a patient suffering from unipolar depression, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is given for treating residual symptoms of depression.

List of claims that had been amended, and how the new claims correspond in format/structure/content to the old claims:

With the sole intention to further assist you with the amended claims please note that:

Claims 1, 2, 3, 6, 42, 43, 48, 49, 53, 54, are Currently Amended,
in addition Applicant has added Claims 55-117 (new) of which:

Claims 55, 56, are corresponding to claim(s) 1, (9, and 41)

Claims 57, 58, are corresponding to claim(s) 2, (9, and 41)

Claims 59, 60, are corresponding to claims 1, 2, and utilizing a definition
explained in the amendment to specifications (pasted and re-entered from
the provisional application)

Claims 61, 62 corresponds to Claim 3, (and is similar to Claim 59)

Claim 63 corresponds to Claim 4,

Claims 64, 65 corresponds to Claim 5,

Claim 66 corresponds to Claim 6,

Claim 67 corresponds to Claim 7,

Claim 68 corresponds to Claim 8,

Claim 69 corresponds to Claim 10,

Claim 70 corresponds to Claim 11,

Claim 71 corresponds to Claim 12,

Claim 72 corresponds to Claim 13,

Claim 73 corresponds to Claim 14,

Claim 74 corresponds to Claim 15,

Claim 75 corresponds to Claim 16,

Claim 76 corresponds to Claim 17,

Claim 77 corresponds to Claim 18,

Claim 78 corresponds to Claim 19,

Claim 79 corresponds to Claim 20,

Claim 80 corresponds to Claim 21,

Claim 81 corresponds to Claim 22,

Claim 82 corresponds to Claim 23,

Claim 83 corresponds to Claim 24,
Claim 84 corresponds to Claim 25,
Claim 85 corresponds to Claim 26,
Claim 86 corresponds to Claim 27,
Claim 87 corresponds to Claim 28,
Claim 88 corresponds to Claim 29,
Claim 89 corresponds to Claim 30,
Claim 90 corresponds to Claim 31,
Claim 91 corresponds to Claim 32,
Claim 92 corresponds to Claim 33,
Claim 93 corresponds to Claim 34,
Claim 94 corresponds to Claim 35,
Claim 95 corresponds to Claim 36,
Claim 96 corresponds to Claim 37,
Claim 97 corresponds to Claim 38,
Claims 98-103 correspond to Claims 42, 48, 53, 54,
Claim 104 corresponds to Claim 51,
Claim 105 corresponds to Claim 52,
Claim 106-108 corresponds to Claim 12, (ketamine is an NMDA receptor
antagonist as also dicussed in the specification)
Claim 109-118 corresponds to the original Claims 1, 2, and Claims 42, 48, 53, 54.